NovaBridge Biosciences (NBP) Enterprise Value (2020 - 2026)

NovaBridge Biosciences (NBP) has reported Enterprise Value for 8 consecutive years, with -$210.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Enterprise Value fell 21.59% year-over-year to -$210.8 million; the TTM figure through Dec 2025 stood at -$210.8 million (down 21.59% YoY), while the FY2025 annual figure was -$210.8 million, down 21.59% from the prior year.
• Enterprise Value improved to -$210.8 million in Q4 2025 per NBP's latest filing, from -$228.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$165.6 million in Q2 2025 and bottomed at -$118.4 billion in Q4 2021.
• Historically, Enterprise Value has averaged -$9.4 billion across 5 years, with a median of -$228.3 million in 2025.
• Annual changes were most pronounced in 2021 — Enterprise Value slumped 16273.69% — and 2022, when it surged 99.59%.
• NovaBridge Biosciences' Enterprise Value stood at -$118.4 billion in 2021, then soared by 99.59% to -$485.0 million in 2022, then surged by 34.58% to -$317.3 million in 2023, then surged by 45.35% to -$173.4 million in 2024, then declined by 21.59% to -$210.8 million in 2025.
• Business Quant data shows NBP's Enterprise Value at -$210.8 million in Q4 2025, -$228.3 million in Q3 2025, and -$165.6 million in Q2 2025.